University of Washington to Initiate Phase 1/2 Trial of Consolidation Therapy After Padcev and Keytruda
REINFORCE Trial with 12 Patients to Address Treatment Gaps
The University of Washington-led Phase 1/2 trial (NCT07579195) targets patients with locally advanced or lymph node/metastatic stage 3 or 4 muscle-invasive bladder cancer. It will enroll 12 patients who achieve complete or partial response per RECIST 1.1 criteria after 3–9 cycles of Padcev and Keytruda induction therapy, assessing the feasibility of localized consolidation therapy. As of July 15, 2026, the trial status is still recruiting, with a start date listed as August 1, 2026. The primary endpoint is the completion rate of protocol treatment within 12 months post-eligibility, with a success threshold set at over 70%.
Local Consolidation to Eliminate Residual Disease After Systemic Therapy
Patients with residual bladder tumors will receive either IMRT or VMAT at 55 Gy in 20 fractions, combined with radiosensitizing chemotherapy, or radical cystectomy with pelvic lymph node dissection. Extravesical residual disease will be treated with 3–5 cycles of SBRT, followed by observation or Keytruda maintenance. While bladder-conserving consolidation is recommended for patients with clinical complete response, it is not mandatory. Currently, integrated therapy for locally advanced or oligometastatic disease remains case-by-case, and this study represents an initial step toward standardizing a treatment pathway.
Expanding Approval Basis for Nectin-4 ADC and PD-1 Inhibitor
Padcev (enfortumab vedotin-ejfv) is an antibody-drug conjugate that targets Nectin-4 and delivers the microtubule inhibitor MMAE, while Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor. The FDA granted accelerated approval for their combination on April 3, 2023, for platinum-ineligible locally advanced/metastatic urothelial cancer, and full approval as first-line therapy on December 15, 2023, based on the EV-302 results. It was further approved on November 21, 2025, for neoadjuvant/adjuvant therapy in platinum-ineligible MIBC, with a hazard ratio of 0.40 for event-free survival and 0.50 for overall survival in KEYNOTE-905/EV-303. REINFORCE differentiates itself by linking these drug effects to a selective post-response radiation/surgery strategy, rather than cystectomy-centered perioperative treatment.
Biomarkers and Competitive Landscape Will Determine Further Development Value
Longitudinal collection of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) will analyze minimal residual disease (MRD) and recurrence signals not captured by imaging. Competing standards include gemcitabine/cisplatin with radical cystectomy, and the durvalumab (PD-L1)-based NIAGARA neoadjuvant/adjuvant therapy approved by the FDA on March 28, 2025, as well as nivolumab (PD-1) adjuvant therapy from BMS. The global bladder cancer market is projected to grow from $6.07 billion in 2025 to $9.52 billion by 2034, but this 12-patient pilot without a control group is more about confirming the feasibility of large-scale randomized trial design than market share shifts. Key metrics for further development include treatment completion rate, grade 3+ toxicity, 12-month progression-free survival, and the FACT-Bl quality of life score.
In the short term, REINFORCE will validate whether 12 patients in a single-arm Phase 1/2 trial can complete radiation or cystectomy after Padcev and Keytruda response, using a success threshold of over 70% completion rate. From an investment perspective, the study is not about extending the use of already FDA-approved Nectin-4 ADC and PD-1 inhibitor, but about broadening the treatment pathway by combining systemic therapy cessation with localized control, offering clinical option value. For researchers, the linkage of ctDNA/utDNA with imaging and cystoscopy results will provide MRD data to support patient selection in future randomized trials. For the industry, it represents a bladder-conserving strategy to compete with the durvalumab-based NIAGARA regimen and nivolumab adjuvant therapy in a bladder cancer market expected to grow from $6.07 billion in 2025 to $9.52 billion by 2034. However, the 12-patient enrollment and 12-month evaluation period are not sufficient to prove survival superiority, so mid-to-long-term value will depend on treatment completion rate, grade 3+ toxicity, progression-free survival outcomes, and whether the trial progresses to Phase 2/3.
Source: ClinicalTrials.gov (api_ct)